Pliant Therapeutics Appoints Gary Palmer, M.D. as Senior Vice President of Medical Affairs
Pliant Therapeutics (Nasdaq: PLRX), a late-stage biotechnology company focused on fibrotic diseases, has appointed Gary Palmer, M.D., MBA as Senior Vice President of Medical Affairs. Dr. Palmer, with over 25 years of global leadership experience, will lead the company's global medical affairs activities, including scientific communications and patient advocacy.
Dr. Palmer's extensive background includes leadership roles at Bristol Myers Squibb, where he led the Worldwide Immunology, Fibrosis and Neuroscience Medical Affairs team. He has also held senior positions at Myovant Sciences, Actelion, Eisai Pharmaceuticals, and Pfizer. His expertise spans pulmonary medicine, immunology, and neurology, with experience in supporting successful and orphan disease products.
Éric Lefebvre, M.D., Chief Medical Officer at Pliant, highlighted Dr. Palmer's experience in building best-in-class Medical Affairs organizations as beneficial for Pliant's growth and portfolio advancement towards commercial stage.
Pliant Therapeutics (Nasdaq: PLRX), un'azienda biotecnologica in fase avanzata focalizzata sulle malattie fibrotiche, ha nominato Gary Palmer, M.D., MBA come Vicepresidente Senior delle Affari Medici. Il Dr. Palmer, con oltre 25 anni di esperienza nella leadership globale, guiderà le attività globali di affari medici dell'azienda, comprese le comunicazioni scientifiche e l'avvocatura per i pazienti.
Il vasto background del Dr. Palmer include ruoli di leadership presso Bristol Myers Squibb, dove ha guidato il team di Affari Medici per l'Immunologia, Fibrosi e Neuroscienze a livello mondiale. Ha anche ricoperto posizioni senior presso Myovant Sciences, Actelion, Eisai Pharmaceuticals e Pfizer. La sua expertise spazia dalla medicina polmonare, immunologia e neurologia, con esperienza nel supportare prodotti per malattie rare e di successo.
Éric Lefebvre, M.D., Chief Medical Officer di Pliant, ha sottolineato l'esperienza del Dr. Palmer nella costruzione di organizzazioni di Affari Medici di livello superiore come vantaggio per la crescita di Pliant e il progresso del suo portafoglio verso la fase commerciale.
Pliant Therapeutics (Nasdaq: PLRX), una empresa biofarmacéutica en etapa avanzada centrada en enfermedades fibróticas, ha nombrado a Gary Palmer, M.D., MBA como Vicepresidente Senior de Asuntos Médicos. El Dr. Palmer, con más de 25 años de experiencia en liderazgo global, dirigirá las actividades globales de asuntos médicos de la empresa, incluidas las comunicaciones científicas y el apoyo a pacientes.
El amplio historial del Dr. Palmer incluye roles de liderazgo en Bristol Myers Squibb, donde dirigió el equipo de Asuntos Médicos de Inmunología, Fibrosis y Neurociencia a nivel mundial. También ha ocupado puestos senior en Myovant Sciences, Actelion, Eisai Pharmaceuticals y Pfizer. Su experiencia abarca medicina pulmonar, inmunología y neurología, con experiencia en el apoyo a productos exitosos y para enfermedades huérfanas.
Éric Lefebvre, M.D., Director Médico de Pliant, destacó la experiencia del Dr. Palmer en la construcción de organizaciones de Asuntos Médicos de primer nivel como beneficiosas para el crecimiento de Pliant y el avance de su cartera hacia la etapa comercial.
Pliant Therapeutics (Nasdaq: PLRX)는 섬유성 질환에 중점을 둔 후기 단계 생명공학 회사로, Gary Palmer 박사(MD, MBA)를 의료 담당 선임 부사장으로 임명했습니다. Palmer 박사는 25년 이상의 글로벌 리더십 경험을 바탕으로 회사의 글로벌 의료 담당 활동, 과학적 소통 및 환자 옹호를 이끌게 됩니다.
Palmer 박사의 폭넓은 배경에는 Bristol Myers Squibb에서 면역학, 섬유증 및 신경과학 의료 담당 팀을 이끌었던 리더십 역할이 포함됩니다. 그는 또한 Myovant Sciences, Actelion, Eisai Pharmaceuticals 및 Pfizer에서 고위직을 역임했습니다. 그의 전문 분야는 호흡기 의학, 면역학 및 신경학이며, 성공적인 질병 치료제와 희귀 질병 제품 지원 경험을 갖추고 있습니다.
Pliant의 최고 의료 책임자 Éric Lefebvre 박사는 Palmer 박사의 뛰어난 의료 담당 조직 구축 경험이 Pliant의 성장과 상업 단계를 향한 포트폴리오 발전에 도움이 될 것이라고 강조했습니다.
Pliant Therapeutics (Nasdaq: PLRX), une société de biotechnologie en phase avancée axée sur les maladies fibrosantes, a nommé Gary Palmer, M.D., MBA au poste de Vice-Président Senior des Affaires Médicales. Le Dr. Palmer, fort de plus de 25 ans d'expérience en leadership mondial, dirigera les activités mondiales des affaires médicales de l'entreprise, y compris les communications scientifiques et le plaidoyer en faveur des patients.
Le vaste parcours du Dr. Palmer comprend des postes de direction chez Bristol Myers Squibb, où il a dirigé l'équipe des affaires médicales en immunologie, fibrose et neurosciences à l'échelle mondiale. Il a également occupé des postes de direction chez Myovant Sciences, Actelion, Eisai Pharmaceuticals et Pfizer. Son expertise couvre la médecine pulmonaire, l'immunologie et la neurologie, avec une expérience dans le soutien de produits pour des maladies pédiatriques et orphelines réussis.
Éric Lefebvre, M.D., directeur médical de Pliant, a souligné que l'expérience du Dr. Palmer dans la création d'organisations d'affaires médicales de premier plan était bénéfique pour la croissance de Pliant et l'avancement de son portefeuille vers une étape commerciale.
Pliant Therapeutics (Nasdaq: PLRX), ein Biotechnologieunternehmen in der späten Phase, das sich auf fibrotische Erkrankungen konzentriert, hat Gary Palmer, M.D., MBA zum Senior Vice President für Medizinische Angelegenheiten ernannt. Dr. Palmer, der über 25 Jahre globale Führungserfahrung verfügt, wird die globalen medizinischen Aktivitäten des Unternehmens leiten, einschließlich wissenschaftlicher Kommunikation und Patientenvertretung.
Dr. Palmers umfangreicher Hintergrund umfasst Führungspositionen bei Bristol Myers Squibb, wo er das Team für Medizinische Angelegenheiten in den Bereichen Immunologie, Fibrose und Neurowissenschaften weltweit leitete. Er hatte auch leitende Positionen bei Myovant Sciences, Actelion, Eisai Pharmaceuticals und Pfizer inne. Seine Expertise reicht von der Pulmonologie über Immunologie bis zur Neurologie und schließt Erfahrungen in der Unterstützung erfolgreicher und seltener Erkrankungsprodukte ein.
Éric Lefebvre, M.D., Chief Medical Officer bei Pliant, hob hervor, dass Dr. Palmers Erfahrung in der Schaffung erstklassiger medizinischer Organisationen vorteilhaft für das Wachstum von Pliant und den Fortschritt seines Portfolios in die kommerzielle Phase ist.
- Appointment of Gary Palmer, M.D., MBA as Senior Vice President of Medical Affairs, bringing over 25 years of global leadership experience
- Dr. Palmer's expertise in pulmonary fibrosis and orphan diseases aligns with Pliant's focus on fibrotic diseases
- Addition of experienced leadership to support Pliant's growth and portfolio advancement towards commercial stage
- None.
Former Bristol Myers Squibb Global Medical Affairs Lead brings over 25 years of experience to Pliant
SOUTH SAN FRANCISCO, Calif., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a late-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today announced the appointment of Gary Palmer, M.D., MBA as Senior Vice President of Medical Affairs. Dr. Palmer will lead the Company’s global medical affairs activities including scientific communications and patient advocacy.
“Gary brings deep global medical affairs leadership and strategic expertise in supporting successful and orphan disease products across a range of therapeutic areas including pulmonary fibrosis,” said Éric Lefebvre, M.D., Chief Medical Officer at Pliant. “Gary’s first-hand experience in building best-in-class Medical Affairs organizations will benefit Pliant as we grow our organization and advance our portfolio toward commercial stage.”
Dr. Palmer joins Pliant with over 25 years of global leadership experience in medical affairs from biopharmaceutical companies of various sizes and stages, and across multiple therapeutic areas including pulmonary medicine, immunology and neurology. Most recently, Dr. Palmer was Senior Vice President of Global Medical Affairs Immunology & Neuroscience at Bristol Myers Squibb Co (BMS). In this role, Dr. Palmer led the Worldwide Immunology, Fibrosis and Neuroscience Medical Affairs team covering a portfolio spanning 4 globally marketed medications and more than 15 development candidates across the areas of pulmonary fibrosis, dermatology, gastroenterology, rheumatology and neurology. Prior to BMS, Dr. Palmer was Senior Vice President for Medical Affairs at Myovant Sciences, prior to the company being acquired by Sumitomo Pharma, where, in partnership with Pfizer, he supported the launch of new products. Prior to Myovant, Dr. Palmer served as Senior Vice President of U.S. Medical Affairs at Actelion, now a Janssen Pulmonology Company, as Chief Medical Officer for Neuroscience at Eisai Pharmaceuticals, Vice President for Global Development & Medical Affairs at BMS and Vice President of Medical Affairs & Managed Markets at Pfizer. Dr. Palmer earned his M.D. in Family Medicine, and a M.B.A. from the University of the Witwatersrand in Johannesburg, South Africa.
About Pliant Therapeutics, Inc.
Pliant Therapeutics is a late-stage biopharmaceutical company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases. Pliant's lead product candidate, bexotegrast (PLN-74809), is an oral, small molecule, dual selective inhibitor of αvß6 and αvß1 integrins that is in development in the lead indications for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis, or PSC. Bexotegrast has received Fast Track Designation and Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) in IPF and PSC and Orphan Drug Designation from the European Medicines Agency in IPF and PSC. Pliant has initiated BEACON-IPF, an adaptive Phase 2b/3 trial of bexotegrast in IPF. Pliant is conducting a Phase 1 study for its third clinical program, PLN-101095, a small molecule, dual-selective inhibitor of αvß8 and αvß1 integrins, that is being developed for the treatment of solid tumors. In addition, Pliant has received regulatory clearance for the conduct of a Phase 1 study of PLN-101325, a monoclonal antibody agonist of integrin α7β1 targeting muscular dystrophies.
For additional information, please visit: www.PliantRx.com. Follow us on social media: X, LinkedIn, and Facebook.
Investor and Media Contact:
Christopher Keenan
Vice President, Investor Relations and Corporate Communications
Pliant Therapeutics, Inc.
ir@pliantrx.com
FAQ
Who is the new Senior Vice President of Medical Affairs at Pliant Therapeutics (PLRX)?
What is Gary Palmer's background before joining Pliant Therapeutics (PLRX)?
What will be Gary Palmer's responsibilities at Pliant Therapeutics (PLRX)?
How does Gary Palmer's experience align with Pliant Therapeutics' (PLRX) focus?
